Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alexion Pharmaceuticals, Inc.
Dana-Farber Cancer Institute
Medical College of Wisconsin
BioNTech SE
Sun Yat-sen University
First Affiliated Hospital of Zhejiang University
Navy General Hospital, Beijing
Institute of Hematology & Blood Diseases Hospital, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences